Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11279946 | 0.82 | POLB (0.39) | MAPTL3MBTL1GAAKMT2ALMNA | |
| SCHEMBL708587 | 0.79 | ALDH1A1 (0.42) | MAPTL3MBTL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1020767 | 0.78 | LMNA (0.46) | MAPTALDH1A1TSHRKDM4EHPGD | |
| SCHEMBL12871730 | 0.76 | TSHR (0.40) | MAPTL3MBTL1ALDH1A1TSHRKDM4E | |
| SCHEMBL22661239 | 0.74 | SMN1; SMN2 (0.40) | MAPTL3MBTL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL23817039 | 0.74 | LMNA (0.42) | MAPTL3MBTL1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL8906827 | 0.74 | ALDH1A1 (0.38) | MAPTL3MBTL1ALDH1A1HSD17B10HPGD | |
| SCHEMBL9456178 | 0.74 | TSHR (0.38) | TSHRLMNA | |
| SCHEMBL9196383 | 0.72 | LMNA (0.38) | MAPTALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL11874229 | 0.71 | LMNA (0.47) | MAPTALDH1A1TSHRKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236407-A1 | Perfluoroalkyl group-containing micelle-forming triiodoaromatic compounds, process for their production and their use as contrast media | SCHERING AG (DE) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236407-A1 | Perfluoroalkyl group-containing micelle-forming triiodoaromatic compounds, process for their production and their use as contrast media | AFF1, AFF4, AFF2 | NLRP3 1995/4885MAPT 2374/4885L3MBTL1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.